Galenica's kidney drug meets endpoint in trial
Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for regulatory filings in the United States, Europe and Switzerland.
Australian scientists have developed a drug that they say may prevent kidney disease and reduce the need for dialysis or transplants among patients already afflicted by the disease.